Health And Wellness Demand And APAC Expansion Will Support A Steady Long Term Outlook

Catalysts

About Treatt

Treatt is a purpose-driven ingredients business that supplies natural flavour and fragrance solutions to global food and beverage customers.

What are the underlying business or industry changes driving this perspective?

• The opening of the Shanghai Commercial and Innovation Center and the IMCD distribution agreement across six Asia Pacific countries could broaden Treatt's reach in a structurally growing region. This may gradually support revenue diversification and reduce reliance on any single geography.
• Customer interest in health and wellness, clean label and sugar reduction solutions is feeding into Treatt's premium categories. However, softer consumer demand in North America and slower premium sales highlight a risk that revenue and mix improvement take longer to feed through to earnings.
• The move into powdered citrus extracts and more price stable citrus products is designed to reduce exposure to raw material volatility. Any further pressure on citrus sourcing and competition in heritage categories could continue to weigh on gross margin and profit before tax.
• Closer alignment with large food and beverage customers, including long-standing relationships and the new partnership with Döhler, may increase Treatt's access to projects. Complexity in managing arm's length arrangements and balancing shareholder interests could limit how quickly this translates into higher earnings.
• Cost discipline measures that delivered £1.4m of savings and a largely cash neutral year, excluding buybacks, show tighter control of overheads. Continued investment in sales, category talent and new capability means operating expenses could remain a drag on net margins if revenue growth falls short of targets.

Assumptions

This narrative explores a more pessimistic perspective on Treatt compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Treatt's revenue will grow by 2.5% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 3.8% today to 6.2% in 3 years time.
• The bearish analysts expect earnings to reach £8.8 million (and earnings per share of £0.15) by about February 2029, up from £5.1 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 18.8x on those 2029 earnings, down from 24.0x today. This future PE is lower than the current PE for the GB Chemicals industry at 26.3x.
• The bearish analysts expect the number of shares outstanding to decline by 0.38% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.66%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Sustained pressure on citrus raw material costs and continued changes in customer buying patterns in heritage citrus could further strain volumes and pricing, which may weigh on revenue and gross margin over time rather than supporting a flat share price outlook.
• If softer consumer demand in key markets such as North America persists for longer than expected, especially in higher value premium categories like health and wellness and tea, earnings and net margins could face ongoing pressure instead of stabilising.
• The company is leaning into long-term growth themes such as sugar reduction, health and wellness, sports nutrition and the expansion of its China and wider APAC presence. If these initiatives gain more traction than currently assumed, revenue and earnings could rise faster than implied by a flat share price view.
• Closer ties with Döhler as a 28% shareholder, customer and supplier, combined with new leadership hires and a refreshed premium offering, may create more project flow and operational efficiencies over time. This could support higher gross margin and profit before tax than a no-change share price would suggest.
• The focus on cost discipline, self-help savings of £1.4m, a largely cash neutral year excluding buybacks and plans for a return to net cash position in FY '26 indicate potential for stronger cash generation. This could eventually support a re rating of the shares if revenue growth returns and net margins improve.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Treatt is £2.2, which represents up to two standard deviations below the consensus price target of £2.84. This valuation is based on what can be assumed as the expectations of Treatt's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £5.54, and the most bearish reporting a price target of just £2.2.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be £142.7 million, earnings will come to £8.8 million, and it would be trading on a PE ratio of 18.8x, assuming you use a discount rate of 7.7%.
  
• Given the current share price of £2.06, the analyst price target of £2.2 is 6.4% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.